ACADIA Pharmaceuticals (NASDAQ:ACAD) Earns Market Outperform Rating from Citizens Jmp

ACADIA Pharmaceuticals (NASDAQ:ACAD)‘s stock had its “market outperform” rating reaffirmed by equities research analysts at Citizens Jmp in a research note issued on Tuesday,Benzinga reports. They currently have a $34.00 target price on the biopharmaceutical company’s stock. Citizens Jmp’s target price would indicate a potential upside of 40.32% from the company’s current price.

Several other research analysts have also weighed in on the company. Needham & Company LLC reiterated a “buy” rating and issued a $34.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Monday, January 5th. Weiss Ratings reiterated a “hold (c+)” rating on shares of ACADIA Pharmaceuticals in a report on Monday, December 29th. UBS Group boosted their price objective on shares of ACADIA Pharmaceuticals from $35.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. JPMorgan Chase & Co. decreased their target price on shares of ACADIA Pharmaceuticals from $33.00 to $31.00 and set an “overweight” rating on the stock in a research report on Monday, November 17th. Finally, Wall Street Zen cut shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, January 31st. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, ACADIA Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $31.25.

ACADIA Pharmaceuticals Trading Down 2.1%

Shares of ACAD opened at $24.23 on Tuesday. ACADIA Pharmaceuticals has a 12-month low of $13.40 and a 12-month high of $28.35. The firm has a market capitalization of $4.10 billion, a P/E ratio of 15.63, a P/E/G ratio of 6.19 and a beta of 0.66. The firm has a 50-day moving average price of $26.53 and a 200 day moving average price of $24.46.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.28. ACADIA Pharmaceuticals had a net margin of 24.94% and a return on equity of 14.61%. The company had revenue of $278.63 million for the quarter, compared to analyst estimates of $276.52 million. During the same period in the previous year, the business posted $0.20 EPS. ACADIA Pharmaceuticals’s revenue was up 11.3% on a year-over-year basis. Equities research analysts predict that ACADIA Pharmaceuticals will post 0.7 earnings per share for the current fiscal year.

Insider Activity

In other ACADIA Pharmaceuticals news, EVP Mark C. Schneyer sold 10,262 shares of the stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $23.69, for a total transaction of $243,106.78. Following the sale, the executive vice president directly owned 53,338 shares in the company, valued at $1,263,577.22. This represents a 16.14% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider James Kihara sold 4,084 shares of the firm’s stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $23.69, for a total transaction of $96,749.96. Following the completion of the transaction, the insider directly owned 25,058 shares of the company’s stock, valued at $593,624.02. This represents a 14.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 44,346 shares of company stock valued at $1,010,957. 26.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ACAD. Geode Capital Management LLC increased its holdings in ACADIA Pharmaceuticals by 2.4% during the 2nd quarter. Geode Capital Management LLC now owns 3,024,097 shares of the biopharmaceutical company’s stock worth $65,238,000 after purchasing an additional 69,584 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of ACADIA Pharmaceuticals by 16.8% during the third quarter. Dimensional Fund Advisors LP now owns 2,798,134 shares of the biopharmaceutical company’s stock worth $59,712,000 after buying an additional 402,534 shares during the period. First Trust Advisors LP raised its holdings in ACADIA Pharmaceuticals by 2.8% in the second quarter. First Trust Advisors LP now owns 2,434,376 shares of the biopharmaceutical company’s stock valued at $52,509,000 after acquiring an additional 65,914 shares in the last quarter. Braidwell LP purchased a new position in ACADIA Pharmaceuticals in the third quarter worth approximately $50,760,000. Finally, Marshall Wace LLP grew its holdings in ACADIA Pharmaceuticals by 19.8% during the 3rd quarter. Marshall Wace LLP now owns 2,358,881 shares of the biopharmaceutical company’s stock worth $50,339,000 after acquiring an additional 389,170 shares in the last quarter. 96.71% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting ACADIA Pharmaceuticals

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: Bullish analyst ratings and price targets reaffirmed — HC Wainwright reiterated a “buy” and a $37 price target (large upside), and Citizens JMP kept a “market outperform” with a $34 target; these support the bull case and could help the stock recover if regulators soften their stance. Read More.
• Positive Sentiment: Zacks singled ACADIA out among five drug/biotech stocks likely to outperform Q4 estimates, suggesting some analysts expect upside to upcoming earnings. Read More.
• Neutral Sentiment: Company set to report Q4 & full‑year 2025 results on Feb 25, 2026 — a scheduled catalyst that could swing the stock either direction depending on guidance and trofinetide sales trends. Read More.
• Neutral Sentiment: Short‑interest data posted is effectively inconclusive (shows 0 shares in the provided snapshot), so there’s no clear short‑squeeze pressure reflected in the report. (Data appears anomalous and should be verified at the exchange level.)
• Neutral Sentiment: Market commentary pieces are assessing whether the recent rebound leaves ACAD attractively valued; useful context for longer‑term investors but not an immediate catalyst. Read More.
• Negative Sentiment: ACADIA expects a negative CHMP opinion on trofinetide in the EU — likely delaying or preventing EU approval and reducing the drug’s near‑term market opportunity in Europe. This directly raises regulatory risk and revenue uncertainty. Read More.
• Negative Sentiment: FDA’s new “PreCheck” process has led to setbacks for several drug candidates including ones tied to Acadia, increasing near‑term regulatory uncertainty in the U.S. for pipeline programs. Read More.
• Negative Sentiment: Commentary and news coverage link an EMA/CHMP setback to a changing bull case for ACAD, signaling that prior upside assumptions (EU launch and associated sales) may need to be revised. Read More.
• Negative Sentiment: After‑hours coverage noted an ~8% slump tied to these regulatory headlines, showing the market is already pricing in the setback and raising the chance of near‑term volatility. Read More.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.